RecruitingNCT07089836

This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.

ALPCO Syphilis-T and Syphilis-NT CLIA Kits: Detection of Antibodies to Treponema Pallidum and Against Lipoidal Antigens in Human Serum and Plasma


Sponsor

American Laboratory Products Company

Enrollment

1,000 participants

Start Date

Dec 10, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study will evaluate the clinical performance of two investigational diagnostic kits developed by ALPCO: the Syphilis-T CLIA Kit and the Syphilis-NT CLIA Kit. These kits are designed to detect antibodies to Treponema pallidum and non-treponemal lipoidal antigens, respectively, in human serum and plasma using the automated KleeYa platform. The study will collect and analyze blood samples from individuals suspected of having syphilis, those at high risk, HIV-positive patients, pregnant individuals, and healthy controls. The aim is to determine the kits' Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) compared to established reference assays.


Eligibility

Min Age: 13 Years

Inclusion Criteria7

  • Male, Female, or Other(s)
  • Patients undergoing routine syphilis testing (asymptomatic at risk, suspected with symptoms, prior history of syphilis, high risk for syphilis) or previously diagnosed with syphilis through a test performed in an accredited laboratory.
  • Participants must be willing to provide the required blood samples for the clinical study, in addition to any samples requested by their physician.
  • Pregnant individuals and children (under 22): 1 clinical study tube of blood.
  • All other participants (excluding pregnant individuals and children): 2 clinical study tubes of blood.
  • Participants must be able and willing to sign the informed consent form (ICF).
  • Participants aged 13 to 17 will be asked to sign an assent form. Written parental or guardian consent will also be required prior to enrollment. The assent form will use age-appropriate language and be reviewed with the participant before any procedures.

Exclusion Criteria4

  • Patients currently being treated with antibiotics or completed a course of antibiotics within the past 30 days
  • Patients with pre-existing conditions that would make blood collection difficult or harmful
  • If the samples are not collected in strict accordance with the established sampling protocol, as determined by the study team.
  • Any medical, psychological, or social condition that, in the judgment of the investigator, could interfere with the participant's ability to comply with study requirements, or pose a risk to their safety, or compromise the integrity of the study.

Interventions

DEVICEALPCO Syphilis-T

Detection of antibodies to Treponema pallidum in human serum and plasma

DEVICEALPCO Syphilis-NT CLIA Kits

Detection of antibodies to lipoidal antigens in human serum and plasma


Locations(6)

Chemidox Clinical Trials California

Lancaster, California, United States

Folio Clinical Research

Los Angeles, California, United States

Segel Trials

North Miami, Florida, United States

IMA Clinical Research - St.Petersburg

St. Petersburg, Florida, United States

Chemidox Tx LLC

Houston, Texas, United States

VAST Clinical Research

Mesquite, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07089836


Related Trials